Exicure (XCUR) Competitors $7.63 +0.05 (+0.66%) As of 11:29 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. CRBU, EPRX, CTMX, ELDN, TVGN, SXTC, OGI, LYEL, CYBN, and RAPTShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include Caribou Biosciences (CRBU), Eupraxia Pharmaceuticals (EPRX), CytomX Therapeutics (CTMX), Eledon Pharmaceuticals (ELDN), Semper Paratus Acquisition (TVGN), China SXT Pharmaceuticals (SXTC), Organigram Global (OGI), Lyell Immunopharma (LYEL), Cybin (CYBN), and Rapt Therapeutics (RAPT). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors Caribou Biosciences Eupraxia Pharmaceuticals CytomX Therapeutics Eledon Pharmaceuticals Semper Paratus Acquisition China SXT Pharmaceuticals Organigram Global Lyell Immunopharma Cybin Rapt Therapeutics Exicure (NASDAQ:XCUR) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Which has more volatility and risk, XCUR or CRBU? Exicure has a beta of 3.67, meaning that its share price is 267% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.55, meaning that its share price is 155% more volatile than the S&P 500. Do insiders and institutionals hold more shares of XCUR or CRBU? 42.8% of Exicure shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 8.4% of Exicure shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend XCUR or CRBU? Caribou Biosciences has a consensus target price of $6.67, indicating a potential upside of 289.18%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Caribou Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is XCUR or CRBU more profitable? Exicure has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,490.84%. Caribou Biosciences' return on equity of -55.70% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -208.96% -88.78% Caribou Biosciences -1,490.84%-55.70%-45.35% Which has higher valuation and earnings, XCUR or CRBU? Exicure has higher earnings, but lower revenue than Caribou Biosciences. Exicure is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K96.44-$9.70M-$3.88-1.97Caribou Biosciences$9.99M15.95-$149.10M-$1.62-1.06 Does the media prefer XCUR or CRBU? In the previous week, Exicure had 3 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Exicure and 1 mentions for Caribou Biosciences. Exicure's average media sentiment score of 0.29 beat Caribou Biosciences' score of 0.00 indicating that Exicure is being referred to more favorably in the media. Company Overall Sentiment Exicure Neutral Caribou Biosciences Neutral SummaryCaribou Biosciences beats Exicure on 10 of the 16 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.13M$3.03B$5.50B$9.75BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-1.9617.3429.9825.02Price / Sales96.44351.60456.40103.38Price / CashN/A40.7324.8128.01Price / Book6.818.908.655.79Net Income-$9.70M-$54.75M$3.26B$265.14M7 Day Performance3.11%-1.60%0.26%0.36%1 Month Performance4.95%6.11%2.80%1.54%1 Year Performance1,427.22%21.70%45.63%26.85% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure1.0551 of 5 stars$7.63+0.7%N/A+1,329.9%$48.13M$500K-1.9650Earnings ReportGap DownCRBUCaribou Biosciences2.4742 of 5 stars$2.06-2.1%$8.50+313.6%-11.9%$192.98M$9.99M-1.28100EPRXEupraxia Pharmaceuticals2.7791 of 5 stars$5.33-1.0%$11.00+106.6%+98.5%$191.49MN/A-7.0129Positive NewsUpcoming EarningsCTMXCytomX Therapeutics3.9987 of 5 stars$2.38-0.6%$5.75+142.1%+92.5%$190.67M$138.10M4.93170Analyst RevisionGap DownELDNEledon Pharmaceuticals1.7024 of 5 stars$3.19-2.0%$10.00+214.0%+3.4%$190.12MN/A-1.5110News CoverageUpcoming EarningsTVGNSemper Paratus Acquisition3.6601 of 5 stars$1.01+1.2%$10.00+895.0%+52.4%$184.81MN/A0.003News CoverageSXTCChina SXT Pharmaceuticals0.59 of 5 stars$1.59+0.3%N/A-80.2%$183.79M$1.74M0.0090OGIOrganigram Global0.7919 of 5 stars$1.37-1.1%N/A+11.6%$182.95M$117.47M13.65860News CoverageUpcoming EarningsLYELLyell Immunopharma2.7912 of 5 stars$11.71+3.0%$15.00+28.1%-65.4%$180.42M$60K-0.47270Upcoming EarningsCYBNCybin2.878 of 5 stars$7.56-1.6%$85.00+1,024.3%N/A$177.99MN/A-1.7250Positive NewsRAPTRapt Therapeutics4.353 of 5 stars$10.61-1.4%$20.57+93.9%-47.4%$175.49M$1.53M-0.5580Earnings ReportAnalyst DowngradeAnalyst Revision Related Companies and Tools Related Companies Caribou Biosciences Alternatives Eupraxia Pharmaceuticals Alternatives CytomX Therapeutics Alternatives Eledon Pharmaceuticals Alternatives Semper Paratus Acquisition Alternatives China SXT Pharmaceuticals Alternatives Organigram Global Alternatives Lyell Immunopharma Alternatives Cybin Alternatives Rapt Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredMy shocking meeting in Washington, D.C.After a shocking discovery in D.C., Jeff Brown is revealing: President Trump’s “Project MAFA” Get a look...Brownstone Research | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | Sponsored#1 Pre-IPO Opportunity For 2025 [Take Action Now!]James Altucher has scored 37X and even 60X returns on past pre-IPO deals. But now he says a much bigger opport...Paradigm Press | SponsoredSilver Demand Is Exploding—and Supply Can’t Keep UpElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access